Source Rock Royalties Ltd. (TSXV:SRR)

Longboard Pharmaceuticals Cash Flow Statement

Financials in millions CAD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	1.63	1.5	1.57	2.56	0.18	-2.86
Depreciation & Amortization	3.7	3.94	3.18	2.18	3.62	5.94
Stock-Based Compensation	0.87	0.84	0.78	0.4	0.31	0.27
Provision & Write-off of Bad Debts	-	-	-	-	-0.01	0.05
Other Operating Activities	-0.24	-0.28	0.13	-0.01	-0.39	-2.37
Change in Accounts Receivable	0.21	0.22	-0.18	-0.27	-0.45	0.13
Change in Accounts Payable	-0.09	-0.07	0.09	-0.1	0.05	0.01
Change in Income Taxes	0.17	0.51	-0.66	0.6	0.08	-
Change in Other Net Operating Assets	-0	-0.01	0.01	-0.04	0.02	-0.02
Operating Cash Flow	6.23	6.65	4.91	5.32	3.41	1.15
Operating Cash Flow Growth	3.65%	35.33%	-7.58%	56.09%	197.30%	-43.91%
Capital Expenditures	-0.03	-0.03	-13.28	-3.62	-1.19	-0.43
Sale (Purchase) of Intangibles	-	-	-	-	-	-0.25
Investing Cash Flow	-0.03	-0.03	-13.28	-3.62	-1.19	-0.68
Issuance of Common Stock	-	0	0.13	13.49	-	-
Repurchase of Common Stock	-	-	-	-0.44	-	-
Common Dividends Paid	-3.52	-3.45	-3.37	-2.02	-1.47	-0.86
Other Financing Activities	-	-	-0.09	-1.07	-0.16	-
Financing Cash Flow	-3.52	-3.45	-3.33	9.96	-1.63	-0.86
Net Cash Flow	2.68	3.17	-11.69	11.66	0.58	-0.4
Free Cash Flow	6.2	6.62	-8.36	1.7	2.21	0.71
Free Cash Flow Growth	-	-	-	-23.18%	211.27%	81.21%
Free Cash Flow Margin	81.23%	86.11%	-125.85%	26.18%	51.90%	51.66%
Free Cash Flow Per Share	0.13	0.14	-0.18	0.04	0.07	0.03
Levered Free Cash Flow	6.22	6.7	-9.32	1.52	2.53	2.13
Unlevered Free Cash Flow	6.22	6.7	-9.32	1.52	2.53	2.13

Updated Nov 28, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.